Guiyuan Lei

1.3k total citations
28 papers, 891 citations indexed

About

Guiyuan Lei is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Guiyuan Lei has authored 28 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Guiyuan Lei's work include Lymphoma Diagnosis and Treatment (12 papers), Advanced Breast Cancer Therapies (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Guiyuan Lei is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Advanced Breast Cancer Therapies (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Guiyuan Lei collaborates with scholars based in United Kingdom, Switzerland and United States. Guiyuan Lei's co-authors include Elisabeth Wassner-Fritsch, Franck Morschhauser, Michael Wenger, Guillaume Cartron, Gilles Salles, Philippe Solal‐Céligny, Catherine Thiéblemont, Réda Bouabdallah, Jianmei Wang and Paul Emery and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Guiyuan Lei

27 papers receiving 881 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guiyuan Lei United Kingdom	12	509	480	343	228	209	28	891
Emanuela Carlotti United Kingdom	10	326 0.6×	164 0.3×	230 0.7×	171 0.8×	115 0.6×	20	579
James T. Sundeen United States	12	554 1.1×	246 0.5×	330 1.0×	240 1.1×	103 0.5×	15	804
Timothy J. Murphy United States	9	799 1.6×	778 1.6×	310 0.9×	399 1.8×	160 0.8×	19	1.2k
W. Hiddemann Germany	2	871 1.7×	432 0.9×	627 1.8×	134 0.6×	156 0.7×	2	969
Klaus Willenbrock Germany	16	558 1.1×	198 0.4×	465 1.4×	291 1.3×	57 0.3×	23	874
Andreas Braeuninger Germany	7	353 0.7×	232 0.5×	209 0.6×	208 0.9×	101 0.5×	11	634
Elisabeth Wassner-Fritsch Switzerland	12	1.1k 2.2×	768 1.6×	743 2.2×	300 1.3×	251 1.2×	20	1.3k
C Lavignac France	8	504 1.0×	249 0.5×	369 1.1×	134 0.6×	46 0.2×	14	836
Nedjad Losic United States	10	551 1.1×	547 1.1×	284 0.8×	304 1.3×	243 1.2×	23	871
Claire Dearden United Kingdom	9	369 0.7×	531 1.1×	197 0.6×	160 0.7×	26 0.1×	16	947

Countries citing papers authored by Guiyuan Lei

Since Specialization

Citations

This map shows the geographic impact of Guiyuan Lei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guiyuan Lei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guiyuan Lei more than expected).

Fields of papers citing papers by Guiyuan Lei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guiyuan Lei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guiyuan Lei. The network helps show where Guiyuan Lei may publish in the future.

Co-authorship network of co-authors of Guiyuan Lei

This figure shows the co-authorship network connecting the top 25 collaborators of Guiyuan Lei. A scholar is included among the top collaborators of Guiyuan Lei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guiyuan Lei. Guiyuan Lei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lei, Guiyuan, et al.. (2025). Therapeutic potential of ADSC-derived exosomes in acute lung injury by regulating macrophage polarization through IRF7/NLRP3 signaling. International Immunopharmacology. 156. 114658–114658.

Juric, Dejan, Kevin Kalinsky, Nicholas C. Turner, et al.. (2024). First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.. Journal of Clinical Oncology. 42(16_suppl). 1003–1003. 23 indexed citations

Jhaveri, Komal, Seock‐Ah Im, Cristina Saura, et al.. (2024). Abstract GS03-13: Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. Cancer Research. 84(9_Supplement). GS03–13. 16 indexed citations

Cheng, Ying, Lin Wu, Yongping Huang, et al.. (2021). P48.08 Phase IV Clinical Study on the Safety and Efficacy of Lobaplatin-Based Regimen With Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S502–S503. 2 indexed citations

Turner, Nicholas C., Komal Jhaveri, Kevin Kalinsky, et al.. (2021). Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC). Cancer Research. 81(4_Supplement). OT–36. 1 indexed citations

Bédard, Philippe L., Komal Jhaveri, Andrés Cervantes, et al.. (2021). Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). Cancer Research. 81(4_Supplement). PD1–2. 4 indexed citations

Xu, Binghe, Wei Li, Qingyuan Zhang, et al.. (2020). Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Research and Treatment. 182(3). 689–697. 29 indexed citations

Turner, Nicholas C., Komal Jhaveri, Kevin Kalinsky, et al.. (2020). 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC). Annals of Oncology. 31. S391–S392. 6 indexed citations

Punnoose, Elizabeth A., Franklin Peale, Edith Szafer‐Glusman, et al.. (2020). BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clinical Lymphoma Myeloma & Leukemia. 21(4). 267–278.e10. 10 indexed citations

10.

Lindeman, Geoffrey J., Aditya Bardia, Rebecca Bowen, et al.. (2019). Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.. Journal of Clinical Oncology. 37(15_suppl). TPS1108–TPS1108. 2 indexed citations

11.

Schneeweiß, Andreas, Hope S. Rugo, Eric P. Winer, et al.. (2019). IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology. 37(15_suppl). 1068–1068. 1 indexed citations

12.

Szafer‐Glusman, Edith, Franklin Peale, Guiyuan Lei, et al.. (2017). BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL. Blood. 130. 418–418. 1 indexed citations

13.

Dyer, Martin J.S., Marcos González, Martin Dreyling, et al.. (2016). Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 102(4). 765–772. 21 indexed citations

14.

Dyer, Martin J.S., Andrew Grigg, Marcos González, et al.. (2014). Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study. Blood. 124(21). 1743–1743. 9 indexed citations

15.

Morschhauser, Franck, Guillaume Cartron, Catherine Thiéblemont, et al.. (2013). Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. Journal of Clinical Oncology. 31(23). 2912–2919. 157 indexed citations

16.

Wang, Jianmei, Adam Platt, Ruchi Upmanyu, et al.. (2013). IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open. 3(8). e003199–e003199. 50 indexed citations

17.

Dyer, Martin J.S., Andrew Grigg, Marcos González, et al.. (2012). Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000). Blood. 120(21). 3686–3686. 6 indexed citations

18.

Isaacs, John D., Stanley Cohen, Paul Emery, et al.. (2012). Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of the Rheumatic Diseases. 72(3). 329–336. 151 indexed citations

19.

Gillespie, Colin S., Guiyuan Lei, Richard J. Boys, Amanda Greenall, & Darren J. Wilkinson. (2010). Analysing time course microarray data using Bioconductor: a case study using yeast2 Affymetrix arrays. BMC Research Notes. 3(1). 81–81. 14 indexed citations

20.

Greenall, Amanda, Guiyuan Lei, Daniel Swan, et al.. (2008). A genome wide analysis of the response to uncapped telomeres in budding yeast reveals a novel role for the NAD+ biosynthetic gene BNA2in chromosome end protection. Genome biology. 9(10). R146–R146. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact